- Home
- OTLK vs REFI Comparison
OTLK vs REFI Comparison
Compare OTLK & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | REFI |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 241.1M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OTLK | REFI |
|---|---|---|
| Price | $1.41 | $10.67 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 11.8M | 200.5K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.79% |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | $8,146,123.00 | ★ $48,857,628.00 |
| Revenue This Year | $1,430.98 | $17.47 |
| Revenue Next Year | $173.23 | $0.06 |
| P/E Ratio | ★ N/A | $47.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $10.56 |
| 52 Week High | $3.39 | $14.57 |
Technical Indicators
Market Signals| Indicator | OTLK | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 42.38 |
| Support Level | $1.21 | N/A |
| Resistance Level | $1.54 | $12.45 |
| Average True Range (ATR) | 0.18 | 0.22 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 17.54 | 12.76 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.